Drug Database
ES

esmolol hydrochoride

✓ Approved

HQ Specialty Pharma · ADRB1 · 小分子

什么是 esmolol hydrochoride?

esmolol hydrochoride 是一种小分子,由HQ Specialty Pharma研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intravenous (IV)。

药物档案

公司HQ Specialty Pharma
药物类别小分子
分子靶点ADRB1
给药途径Injectable (Others), Intravenous (IV)
状态Approved

作用机制

分子靶点

esmolol hydrochoride 作用于 1 个分子靶点:

ADRB1adrenoceptor beta 1 (B1AR, RHR)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

esmolol hydrochoride 针对 3 个适应症,涉及 2 个治疗领域。

治疗领域疾病/病症分期
Cardiac disordersAtrial fibrillation✓ Approved
Vascular disordersHypertension✓ Approved
Cardiac disordersSupraventricular tachycardia✓ Approved

相关研究文献

PubMedThe American journal of emergency medicine2026-11-18

Co-administration of adrenaline and landiolol during cardiopulmonary resuscitation in a swine model of ventricular fibrillation.

Gripiotis Ioannis I, Stroumpoulis Konstantinos K, Mavrovounis Georgios G, Karampela Eleftheria E et al.

We examined whether early co-administration of landiolol and adrenaline improves successful extubation, hemodynamics, and 48-h outcomes in a swine ventricular fibrillation (VF) model. In this prospective, randomized, investigator-blinded study, VF was electrically induced in healthy piglets and left untreated for 8 min. Thirty-nine female Landrace/Large White piglets were randomized (1:1:1): adrenaline 0.02 mg/kg plus saline, adrenaline plus esmolol 0.5 mg/kg, or adrenaline plus landiolol 0.02 mg/kg. Treatment was administered at the initiation of mechanical cardiopulmonary resuscitation (CPR), 2 min before attempting defibrillation. Primary outcome was successful extubation. Secondary outcomes included return of spontaneous circulation (ROSC), 48-h survival, 48-h survival with complete neurological recovery, and hemodynamic variables during and after CPR. Successful extubation occurred in 2/13 (15%) control, 6/13 (46%) esmolol, and 9/13 (69%) landiolol animals (overall p = 0.021); the rate was significantly higher with landiolol than with control (adjusted p = 0.046). ROSC rates were 46%, 69%, and 100%, respectively (p = 0.006); 48-h survival rates were 8%, 31%, and 54% (p = 0.046); and 48-h survival with complete neurological recovery rates were 0%, 23%, and 46% (p = 0.022). The landiolol group had higher observed rates of ROSC and 48-h survival with complete neurological recovery than the control group; these secondary analyses were exploratory. No pairwise difference was significant for 48-h survival. Exploratory analyses during the first 4 min of CPR identified higher observed values for selected hemodynamic variables and end-tidal carbon dioxide in the landiolol group at specific time points. Esmolol had intermediate observed outcome rates. Early administration of landiolol with adrenaline was associated with a higher successful extubation rate and better observed early CPR hemodynamics compared with adrenaline alone and had the highest rates of ROSC, 48-h survival, and 48-h survival with complete neurological recovery. Secondary-outcome findings were exploratory, and landiolol was not statistically superior to esmolol.

PMID 43050784
阅读全文 →
PubMedFrontiers in neuroscience2026-11-10

Effect of ultrasound-guided stellate ganglion block on intraoperative hemodynamics in laparoscopic partial adrenalectomy: a randomized clinical trial.

Nie Jingyi J, Wang Huang H, Zhang Wenjing W, Wang Hui H et al.

This study aimed to evaluate the effect of ultrasound-guided stellate ganglion block (SGB) on intraoperative hemodynamic parameters in patients undergoing laparoscopic partial adrenalectomy. A total of 72 patients with adrenal tumors scheduled for laparoscopic partial adrenalectomy were enrolled and randomly assigned in a 1:1 ratio to either the stellate ganglion block (SGB) group or the control group. The primary outcome was the incidence of intraoperative hypertension, defined as a systolic blood pressure (SBP) ≥180 mmHg or an increase of ≥30% in mean arterial pressure (MAP) from baseline. Secondary outcomes included MAP and heart rate (HR) measured at nine predefined perioperative time points, intraoperative vasoactive drug consumption, and the incidence of perioperative adverse events. The incidence of intraoperative hypertension was significantly lower in the SGB group than in the control group (14.3% vs. 37.1%, p = 0.029). Compared with the control group, patients in the SGB group exhibited significantly lower MAP and HR at eight time points ranging from immediately after tracheal intubation until the end of surgery (p < 0.05). The intraoperative consumption of phentolamine was significantly lower in the SGB group than in the control group [0 (0-4) mg vs. 0 (0-0) mg; p = 0.008]. In contrast, the consumption of norepinephrine was significantly higher in the SGB group [0 (0-0) mg vs. 0 (0-8) mg; p = 0.004]. No statistically significant differences were observed between the two groups in the consumption of esmolol and atropine, or in the incidence of perioperative adverse events. Ultrasound-guided SGB lowers intraoperative hypertension incidence and phentolamine demand in laparoscopic partial adrenalectomy. Although the SGB group observed a slight increase in the intraoperative dose of norepinephrine, no perioperative adverse events occurred. There was also no significant difference in the incidence of adverse reactions between the two groups.

PMID 43005334
阅读全文 →
PubMedBMC anesthesiology2026-10-30

What triggers intraoperative blood pressure/heart rate surges and postoperative hypertonia during unilateral biportal endoscopy?

Sun Peipei P, Ma Tingting T, Ju Jing J, Pan Min M et al.

Unilateral biportal endoscopy (UBE) is an increasingly utilized minimally invasive technique for lumbar degenerative disease. Dural tear is a recognized complication (incidence 1.9-5.8%), typically associated with cerebrospinal fluid leakage and intracranial hypotension. However, the unique irrigation dynamics of UBE - an open two-portal system permitting high-flow continuous irrigation - may produce a distinctly different pathophysiology when an occult dural defect is present. The anesthesiology literature contains few descriptions of the acute intraoperative hemodynamic manifestations of this phenomenon. A 49-year-old woman (ASA physical status I) underwent UBE for L4-L5 and L5-S1 disc herniation under total intravenous anesthesia. The procedure was complicated by intraoperative wrong-level surgery (L4-L5 misidentified as L5-S1), necessitating complete portal withdrawal, re-localization, and re-establishment of the surgical field, which prolonged the operation to 4 h 23 min with a cumulative irrigation volume of 51,000 mL. Approximately 2.5 h after incision, progressive, treatment-refractory tachycardia (70 → 117 beats/min) and hypertension (up to 183/102 mmHg) developed; esmolol and urapidil produced minimal antihypertensive effect despite concurrent augmentation of anesthetic depth. On postoperative review, the scrub nurse recalled observing a suspected dural tear approximately 10 min before the hemodynamic escalation, which had not been communicated intraoperatively. Following extubation, the patient exhibited impaired consciousness, persistent tachypnea (40-50 breaths/min), and generalized hypertonia with decerebrate posturing. Multidisciplinary evaluation excluded epileptic seizure, metabolic encephalopathy, malignant hyperthermia, and intraoperative awareness. Suspected acute intracranial hypertension secondary to massive irrigation fluid entry into the subarachnoid space via the unrecognized dural defect was considered the most likely diagnosis. The patient was reintubated and managed in the intensive care unit with osmotic diuresis (furosemide, mannitol), corticosteroids, and sedation. Consciousness recovered the following morning, limb hypertonia resolved by postoperative day 11, and the patient was discharged on day 14 without neurological deficit. This case suggests that an occult dural tear during UBE with large-volume irrigation may produce a paradoxical hemodynamic profile of progressive, therapy-resistant hypertension and tachycardia - contrasting with the bradycardia and hypotension classically associated with intracranial hypotension from cerebrospinal fluid leaks. The triad of (i) progressive, treatment-refractory hypertension and tachycardia, (ii) prolonged UBE duration (> 2 h), and (iii) large-volume irrigation (> 20 L) may represent a high-risk pattern warranting immediate intraoperative communication between anesthesia and surgical teams and consideration of intracranial pressure-directed interventions. This observation is hypothesis-generating and requires validation in larger studies.

PMID 42958471
阅读全文 →
PubMedCardiovascular therapeutics2026-10-12

Esmolol Alleviates Sepsis-Associated Myocardial Injury by Acting on the APAF1 and JAK2/STAT3 Inflammatory Pathways.

Zhao Lei L, Dong Hua H, Dong Shimin S

The aim of this study is to explore the protective effect of esmolol against sepsis-associated myocardial injury (SAMI) and its underlying molecular mechanisms. SAMI-related differentially expressed genes were identified from the Gene Expression Omnibus database (GSE267388). Potential targets of esmolol were predicted using PharmMapper. Overlapping genes were used for enrichment and molecular docking analyses. H9C2 cells were treated with LPS to establish an injury model, followed by esmolol treatment. Cell viability, apoptosis, oxidative stress, and mitochondrial function were also assessed. The expressions of apoptotic protease activating factor 1 (APAF1) and JAK2/STAT3 pathway molecules were detected using reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and Western blotting. A rat model of sepsis was used to verify cardiac function, inflammation, oxidative stress, and related protein expression. Six core targets were screened, and esmolol showed the strongest binding to APAF1. Esmolol increased cell viability; reduced apoptosis, ROS, and MDA; restored mitochondrial membrane potential; downregulated APAF1, Bax, cleaved-caspase-9/3; and suppressed JAK2/STAT3 phosphorylation. Esmolol reversed APAF1 overexpression-induced injury. In vivo, esmolol alleviated myocardial pathological injury, decreased the concentrations of myocardial markers and inflammatory factors, and inhibited the APAF1 and JAK2/STAT3 pathways. Esmolol protects against SAMI by dual inhibition of the APAF1 mitochondrial apoptotic and JAK2/STAT3 inflammatory pathways, with APAF1 likely serving as a key downstream target of esmolol.

PMID 42861774
阅读全文 →
PubMedAmerican journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists2026-10-12

Labetalol-induced hyperkalemia in acute aortic dissection: A rare but clinically relevant adverse effect.

Butt Faizan F, Khan Zoha Z, Badua Paul M PM

Hyperkalemia is a potentially life-threatening electrolyte abnormality often associated with renin-angiotensin-aldosterone system (RAAS) inhibitors, renal dysfunction, or potassium-sparing agents. Non-selective beta-blockers, including labetalol, may also precipitate hyperkalemia through beta-2 (β-2)-adrenergic blockade, although this adverse effect is underrecognized, particularly in patients without underlying renal disease. A 59-year-old man with hypertension, diabetes, asthma, and polysubstance use disorder presented with severe chest pain and hypertensive emergency (243/132 mmHg). Imaging revealed aortic dilatation and confirmed acute type B aortic dissection. After initial medical management with intravenous (IV) esmolol and nicardipine, oral labetalol was initiated and escalated to 600 mg for anti-impulse therapy. The patient developed persistent, non-hemolyzed hyperkalemia (5.2 to 5.8 mmol/L) temporally correlating with labetalol dose escalation, despite preserved renal function (serum creatinine 1.4 to 1.8 mg/dL) and absence of RAAS inhibitors or heparin exposure. Conservative management failed, and the patient underwent thoracic endovascular aortic repair (TEVAR) with thoracic branch endoprosthesis (TBE). Post-operatively, labetalol was discontinued and replaced with carvedilol. Serum potassium (K+) normalized within 48 hours and remained without further K+ lowering agents. Naranjo Adverse Drug Reaction Probability Scale assessment yielded a score of 7, indicating a probable adverse drug reaction. Labetalol may induce clinically significant hyperkalemia independent of renal impairment or typical precipitating medications. This case highlights the importance of monitoring K+ in patients receiving labetalol for acute aortic syndromes and supports carvedilol as a potentially safer non-selective beta-blocker alternative with respect to K+ homeostasis.

PMID 42862110
阅读全文 →
PubMedInternational journal of biological macromolecules2026-09-30

Electrospun silk sericin-poly(lactic acid) coaxial nanofiber scaffold for esmolol and ferulic acid co-delivery in expedited diabetic wound healing.

Pandey Giriraj G, Kolipaka Tejaswini T, Yadav Deepankar D, Arya Dilip Kumar DK et al.

Diabetic foot ulcers (DFUs) are chronic, infection-prone wounds that heal poorly due to impaired angiogenesis, persistent inflammation, and elevated oxidative stress, creating a substantial clinical and economic burden and highlighting the need for advanced extracellular matrix-mimicking dressings. Therefore, we have developed a ferulic acid (FA)-esmolol (ESM)-loaded coaxial nanofibrous (NFs) scaffold using silk sericin (SS) as the shell and poly(lactic acid) (PLA) as the core via electrospinning for DFU management. The optimized scaffold showed a uniform, bead-free morphology with increased fiber diameter (370 ± 95 nm) compared to blank NFs (201 ± 52 nm) and a confirmed core-shell architecture. The FA-ESM NFs demonstrated high porosity (81.04 ± 4.39%) and an optimal water vapor transmission rate (WVTR) (2077 g/m2/day), supporting a moist wound environment. Water retention (409.39 ± 12.41%) and controlled biodegradation (~98% over 21 days) indicated excellent exudate handling and sustained structural integrity. Mechanical analysis showed suitable tensile strength (1.20 MPa) and elongation (112.80%). Drug release followed the Korsmeyer-Peppas model (R2 ≈ 0.975/0.9811; n = 0.699/0.883), indicating anomalous to case II transport. The scaffold exhibited significant antioxidant activity, >80% cell viability, and hemocompatibility. It significantly enhanced cell migration within 48 h and modulated biomarkers (↓MMP-9, ↓TNF-α, ↑VEGF; p < 0.01). Strong antibacterial activity against Staphylococcus aureus and Pseudomonas aeruginosa, along with significantly accelerated wound closure in diabetic models within 16 days (p < 0.0001), further validates its therapeutic efficacy. Overall, the scaffold demonstrates promising anti-inflammatory, antioxidant, and pro-angiogenic properties and potentially effective dressing for DFU management.

PMID 42815666
阅读全文 →

注册免费账户还可查看另外 1645 篇文献

免费注册查看全部文献 →

了解更多esmolol hydrochoride